Summary
Following resection of their tumour, 162 patients with colorectal cancer entered a prospective randomized controlled clinical trial of adjuvant oral razoxane. Thirty-one patients were Duke’s group A; 49 group B; 61 group C; and 17 group D; an additional four patients were randomized in error.
The adjuvant group received the usual clinical care and 125 mg razoxane twice daily for 5 consecutive days (Monday–friday) every week indefinitely. Control patients received the same clinical care as the adjuvant group, but no razoxane. At 3 years, 134 patients (84%) are evaluable.
The recurrence rate in the first 6 months was 20% and 28% respectively in the Duke’s B and C controls compared with 4% and 9% in the corresponding razoxane treated patients. Most recurrences occurred within the first 6 months from randomization.
When all patients as randomized are included in the analysis of survival, irrespective of whether they were cured by surgery (Duke’s A), had advanced cancer (Duke’s D), or took no razoxane when randomized to take it, then as might be expected any differences there may be between the razoxane-treated and control patients with minimal residual disease (Duke’s B and C) are so distorted that the p value of the difference in survival was 0.93. If however only patients with Duke’s group B or C are taken (49 controls and 47 treated), log-rank analysis reveals a difference in the cancer mortality curves (p = 0.07).
If patients who had been randomized to take razoxane, but who had not taken it at any time (and therefore received the same treatment as controls) are analysed with the controls, the difference between the two groups increases further, with p < 0.05.
The razoxane-treated patients experienced no significant toxicity apart from a readily reversible mild leukopenia in 52% while gastrointestinal symptoms necessitated stopping the drug in only four patients. These four all took the drug for less than 4 weeks.
Because there was no toxicity to subtract from any benefit razoxane adjuvant treatment produced and the quality of life was not impaired, the therapeutic benefit of surgery was increased to the extent that razoxane increased survival of patients with Duke’s B and C tumours.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bakowski MT (1976) ICRF 159 ((±)1,2-bis(3,5-dioxopiperazin-l-yl)propane NSC-129,943; Razoxane. Cancer Treat Rev 3: 95–197
Bellet RE, Engstrom PF, Catalano RB, Creech RH, Mastrangelo MJ (1976) Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy. Cancer Treat Rep 60: 1395–1397
Davis HL, Kisner DL (1978) Analysis of adjuvant therapy in large bowel cancer. Cancer Clin Trials 1: 273–287
Gill PG, Morris PJ (1978) The survival of patients with colorectal cancer treated in a regional hospital. Br J Surg 65: 17–20
Hallowes RC, West DG, Hellmann K (1974) Correlation of cumulative cytostatic effect of ICRF-159 with cellular changes. Nature 247: 487– 490
Hellmann K, Burrage K (1969) Control of malignant metastases by ICRF 159. Nature 224: 273
Higgins GA Jr, Lee LE, Dwight RW, Keehn RJ (1978) The case for adjuvant 5-fluorouracil in colorectal cancer. Cancer Clin Trials 1: 35–41
LeServe AW, Hellmann K (1972) Metastases and the normalization of tumour blood vessels by ICRF 159: A new type of drug action. Br Med J 1: 599
Marciniak TA, Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ (1975) Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma. Cancer Chemother Rep 59: 761
Moertel CG (1978) Chemotherapy of gastrointestinal cancer. N Engl J Med 299: 1049–1052
Salsbury AF, Burrage K, Hellmann K (1974) Histological analysis of the antimetastatic effect of ICRF 159. Cancer Res 34: 843–849
Sharpe BA, Field EO, Hellmann K (1970) The mode of action of the cytostatic agent ICRF 159. Nature 226: 524
Slaney G (1971) Results in treatment of carcinoma of the colon and rectum. In: Irvine WT (ed) Modern trends in surgery, vol 3. Butterworths, London p. 69
Spratt JS, Spjut HJ (1967) Prevalence and prognosis of individual clinical and pathological variables associated with colorectal carcinoma. Cancer 20: 1976–1985
Wood DA, Robbins GF, Zippin C, Lum D, Stearns M (1979) Staging of cancer of the colon and cancer of the rectum. Cancer 43: 961–968
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Gilbert, J.M. et al. (1981). A Controlled Prospective Trial of Adjuvant Razoxane in Resectable Colorectal Cancer. In: Klein, H.O. (eds) Chemotherapy and Radiotherapy of Gastrointestinal Tumors. Recent Results in Cancer Research, vol 79. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81681-9_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-81681-9_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81683-3
Online ISBN: 978-3-642-81681-9
eBook Packages: Springer Book Archive